Show results for
Refine by
Heart Failure Explored On New Episode Of The Heart Failure Services In Europe
5 services found
by:Genome Biologics based inFrankfurt am Main, GERMANY
HFrEF occurs when the left ventricular ejection fraction (LVEF) is 40% or less and is accompanied by progressive left ventricular dilatation and adverse cardiac remodelling. Worldwide, the burden of heart failure has increased to an estimated 23 million people, and approximately 50% of cases are HF-rEF. Despite several therapeutic options, heart failure with reduced ejection fraction remains a ...
by:ReportLinker based inLyon, FRANCE
Life insurance represents the leading market segment with almost 58% of the overall market in terms of value. The EU represents just over 35% of the overall global insurance market. Developed markets dominate the global insurance industry (one of the most profitable financial services), with the US, the UK, Germany, France and Japan holding the largest combined share, reports Global Industry ...
by:Genome Biologics based inFrankfurt am Main, GERMANY
Loss of cardiomyocytes (heart cells) is the primary hallmark of heart failure. However, unlike other cell types, there is a limited capacity for cardiomyocytes proliferation in the adult heart and in the failing human heart. Therefore, regenerative approaches to replenish the lost cardiomyocytes are necessary to recover the contractile capacity of the heart and prevent death. Targeting ...
by:LumiraDx UK Limited based inLondon, UNITED KINGDOM
People living with long-term conditions can play a significant role in managing and improving their own ...
by:ICON plc based inDublin, IRELAND
ICON's cardiovascular trial experience, supported by a global team of experts. ICON has extensive experience in cardiovascular clinical research trials across the entire drug development spectrum. There is still significant unmet need within select cardiovascular/metabolic (CVM) disorders. Unfortunately, the cost of developing drugs and devices in this area has been rising steadily. ICON, a full ...